Tuesday, October 18, 2022 from 1:15 PM to 2:45 PM PDT at Imperial Ballroom B
Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-22-187-L01-P
Activity Type: An Application-Based Activity
The rapid pace of changing guidelines and the growing number of co-morbidities associated with endocrine disorders (and changing treatment recommendations for these co-morbidities) contribute to the gap in knowledge and skills required for pharmacist practicing in the area of endocrine and metabolism is expanding to management of co-morbidities including chronic kidney disease. This session will offer an update on treatment of diabetes related chronic kidney disease and the role of SGLT-2 Inhibitors in treatment.
 | Moderator: Sara W. Reece, Pharm.D., FCCP, BCACP
Associate Professor and Vice Chair, Pharmacy Practice, and Director of IPE, Philadelphia College of Osteopathic Medicine Georgia Campus School of Pharmacy;
Ambulatory Care Pharmacist and Core Faculty, Northeast Georgia Medical Center Family Medicine GME Program
Gainesville, Georgia
View Biography |
Learning Objectives
1. Summarize the updated guidelines for diabetes related chronic kidney disease and role of SGLT-2 inhibitors in CKD.
2. Demonstrate the evidence that supports the use of SGLT-2 inhibitors in persons with diabetes related kidney disease when eGFR is less than or equal to 30 ml/min/1.73sq.m.
3. Apply the evidence that limits use of SGLT-2 inhibitors in persons with diabetes related kidney disease when eGFR is less than or equal to 30 ml/min/1.73sq.m.